Pasithea Therapeutics Corp. (KTTA)
Develops experimental drugs targeting brain disorders, genetic diseases, and certain cancers
$0.44-0.02%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-36.9%
The outlook
KTTA is trading near its 52-week low, well below both its 50- and 200-day moving averages, reflecting a weak near-term trend. Analyst coverage leans bullish with an average price target about 5.8x the current price, though the overall StockGlow score is bearish. The stock sits at the lower end of its yearly range.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range9% of the way from its 52-week low to high
Price targetAvg target +582% vs current price
Market cap
$14.7M
52-wk high
$2.06
52-wk low
$0.28
50-day avg
$0.58
200-day avg
$0.77
Trailing P/E
—